Multidisciplinary treatment strategies for the assessment of immune, coagulation, and biomarker responses after transarterial chemoembolization for hepatocellular carcinoma

Table 6 Comparative analysis of safety assessment between the two groups, n (%)

	Experimental group (n = 45)	Control group (n = 44)	χ2	P value
Adverse reaction	5 (11.11)	13 (29.55)	4.686	0.030
Decreased appetite	1 (2.22)	2 (4.55)
Diarrhea	1 (2.22)	1 (2.27)
Headache	0 (0.00)	1 (2.27)
Lethargy	1 (2.22)	3 (6.82)
Liver function damage	0 (0.00)	1 (2.27)
Rash	1 (2.22)	1 (2.27)
Abnormal blood pressure	0 (0.00)	1 (2.27)
Heart function abnormalities	0 (0.00)	1 (2.27)
Reactive telangiectasia	1 (2.22)	2 (4.55)